I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

In Asians, studies suggest a high prevalence of intracranial atherosclerotic disease (ICAD), with rates up to 33% to 50% in ethnic South Asians,\[[@ref1][@ref2][@ref3]\] making ICAD the most common cause of stroke worldwide.\[[@ref4][@ref5]\] Patients with symptomatic ICAD have elevated risk of recurrent stroke of 12% in the first one year despite best medical therapy,\[[@ref6]\] and as high as 38% in some cohort studies.\[[@ref7]\] This risk is non-linear with approximately half of the risk occurring in the first month.\[[@ref8][@ref9][@ref10]\] Studies from Asia\[[@ref9]\] have reported lower risk of recurrent stroke as compared to Western population. Small studies from India\[[@ref11][@ref12]\] have reported similar patterns of recurrent stroke risks in patients with ICAD. However, detailed imaging analysis, quality of stroke care, and outcomes are scarce in South Asians cohorts with ICAD. Furthermore, whether South Asians with symptomatic ICAD fare differently compared to the Western patients with ICAD is unknown. Our aim was to compare risk factors, presentation, severity, treatment, and outcomes in patients with symptomatic ICAD from Kerala, India with a cohort from Chicago, United States (US).

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Study population {#sec2-1}
----------------

Consecutive patients over 18 years of age with symptomatic ICAD defined by ≥50% stenosis or occlusion were enrolled between 2012 and 2017 at two academic centers: Sree Chitra Tirunal Institute for Medical Sciences and Technology in Thiruvananthapuram, Kerala, India and Northwestern Memorial Hospital in Chicago, IL, United States. The local institutional ethics boards approved the study at each site.

Patients with confirmed acute ischemic stroke (AIS) or transient ischemic attack (TIA) in the territory distal to a stenosis or occluded intracranial artery involving any of the following arteries were included: intracranial internal carotid artery (ICA), proximal (M1 or M2) middle cerebral artery (MCA), proximal (P1) posterior cerebral artery (PCA), proximal (A1) anterior cerebral artery (ACA) intracranial (V4) vertebral artery (VA), and basilar artery (BA). Stenosis of the vessel was determined using modified WASID method on CTA, or DSA when available, with moderate stenosis defined at 50-69% stenosis and severe stenosis or occlusion defined as ≥70% stenosis. Among those with only MRA performed, we measured degree of stenosis as ≥50% by the modified WASID method and further categorized stenosis as 50-69% when flow gap was not present and ≥70 stenosis when flow gap was present.\[[@ref6][@ref13]\] Symptomatic ICAD required that the infarct on DWI or CT (for AIS) or the referable symptoms (for TIA) were localized to the vascular distribution of the stenotic artery without another causative mechanism found on diagnostic testing.

Baseline data collection {#sec2-2}
------------------------

We prospectively collected data on demographics (age, sex, and race/ethnicity), initial National Institute of Health Stroke Scale (NIHSS) score during index hospitalization, risk factors, hospital course, and treatments were collected. Baseline brain and vascular imaging was independently reviewed for presence of acute infarcts on DWI or CT along with location, degree of stenosis, and vascular territory, blinded to outcome data. We also collected data on provision of acute reperfusion therapy defined as intravenous thrombolysis or endovascular treatments in eligible patients presenting within 24 hours of symptom onset.

Medical treatments at discharge {#sec2-3}
-------------------------------

We collected data on medications at discharge including antiplatelet therapy (aspirin, clopidogrel, extended release dipyridamole plus aspirin), anticoagulants (warfarin and non-vitamin K antagonists), statin therapy, antihypertensive medication, and anti-diabetic medications (e. g., oral hypoglycemic agents, insulin).

**Outcomes at 3 months**: Using a standardized questionnaire administered by trained research staff, patients or proxies were contacted to determine events after hospital discharge. Recurrent AIS in the territory of the symptomatic artery within 90 days of index event was the primary outcome. The functional outcome at 90 days was recorded using the modified Rankin Scale (mRS).\[[@ref14]\] Poor outcome was defined as mRS \> 2.

Statistical analysis {#sec2-4}
--------------------

Data are expressed as number (percent), mean (standard deviation \[SD\]), or median (interquartile range \[IQR\]) as appropriate. Baseline, treatment, and outcome data were compared between the US and Indian cohorts using Fisher\'s exact test. A *P* value \< 0.05 was considered significant in univariate comparisons. All analyses were done using Statistical Package for Social Sciences version 23.0 (IBM, Armonk, NY).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Three-hundred twenty-nine patients (117 from India, 212 from US) were included.

CT angiography was the best imaging modality for diagnosis of ICAD in 67%, MR angiography in 25%, and DSA in 8% of patients.

Baseline demographic and clinical characteristics {#sec2-5}
-------------------------------------------------

All the clinical and demographic characteristics are given in [Table 1](#T1){ref-type="table"}. Indian patients were younger (61 vs. 68 years, *P* \< 0.001), less frequently had prior stroke history (15.4% vs. 32.5%, *P* = 0.001), and coronary artery disease (11.1 vs. 22.2%, *P* = 0.013), but more frequently had diabetes mellitus (64.9% vs 51.9%, *P* = 0.027). Indian patients had higher initial NIHSS (median 6 vs. 3, *P* \< 0.001). Though smoking was similar between groups, smoking was more common in Indian males (38.9% vs. 20.1%, *P* = 0.007).

###### 

Demographics, clinical characteristics and outcome of patients

                                        India (*n*=117)   US (*n*=212)   *P*
  ------------------------------------- ----------------- -------------- ---------
  Mean age in years (SD)                60.9 (10.6)       68.2 (12.2)    \<0.001
  Male, *n* (%)                         72 (61.5)         119 (56.1)     0.341
  Hypertension, *n* (%)                 95 (81.2)         176 (83.0)     0.39
  Diabetes, *n* (%)                     77 (65.8)         110 (51.9)     0.02
  Hyperlipidemia, *n* (%)               87 (74.3)         152 (71.7)     0.6
  Prior stroke, *n* (%)                 18 (15.4)         69 (32.5)      0.001
  CAD, *n* (%)                          13 (11.1)         47 (22.2)      0.013
  Current smoking, *n* (%)              28 (23.9)         38 (17.9)      0.193
  Anti-platelet medication, *n* (%)     14 (13.0)         94 (44.5)      \<0.001
  Statin medication, *n* (%)            10 (8.5)          99 (46.9)      \<0.001
  Median NIHSS score (IQR)              6 (2.5-10.5)      3 (1-6)        \<0.001
  Stenosis location, *n* (%)                                             
   Intracranial ICA                     36 (31.6)         48 (22.6)      
   MCA                                  47 (41.2)         81 (38.2)      0.004
   Intracranial VA                      14 (12.3)         39 (14.2)      
   Basilar artery                       12 (10.5)         24 (11.3)      
   ACA                                  3 (2.6)           7 (3.3)        
   PCA                                  2 (1.8)           22 (10.4)      
  Reperfusion therapy, *n* (%)          36 (31.6)         15 (7.1)       0.630
  DAPT on discharge, *n* (%)            106 (90.6)        125 (59.0)     \<0.001
  Statin on discharge, *n* (%)          117 (100)         196 (92.5)     0.002
  3-month outcome of vascular events                                     
   Recurrent ischemic stroke, *n* (%)   2 (1.7)           46 (21.7)      \<0.001
   Recurrent TIA, *n* (%)               8 (6.8)           4 (1.9)        0.03
   Other vascular events, *n* (%)       1 (0.85)          1 (0.47)       0.58
   Good outcome (mRS \<2), *n* (%)      70 (64.2)         148 (70.1)     0.31

Indian patients with diabetes had more severe stroke compared to non-diabetics (median NIHSS 7 vs 4, *P* = 0.009). For US patients, age, gender, diabetes, hypertension, prior history of stroke, CAD, or smoking did not affect stroke severity significantly. Patients on antiplatelets prior to stroke had milder strokes (median NIHSS 3 vs 4.5, *P* = 0.014).

Both groups received reperfusion therapy in similar proportions (8.5% vs. 7.1%, *P* = 0.630). At discharge, 90.6% of Indian patients compared to 59.0% of Chicago patients were treated with dual antiplatelet therapy (*P* \< 0.001). Indian patients were also more likely to be discharged on statin therapy (100% vs. 92.5%; *P* \< 0.002).

Follow-up data {#sec2-6}
--------------

More recurrent strokes occurred in US patients (21.7% vs. 1.9%, *P* \< 0.001), though functional outcome did not differ significantly. Of the 46 patients in the US cohort with recurrent strokes, 25 (54.3%) were black, 16 (34.7%) were white and 5 (11%) were other (Hispanic/mixed). Indian patients were more likely to have recurrent TIA as compared to US patients (6.8% vs 1.9%, *P* = 0.03). Patients with ≥70% stenosis were more likely to have poor functional outcomes at 3 months (35.8% vs. 20%, *P* = 0.009). The 3 month functional outcome significantly correlated with initial stroke severity (r = 0.568, *P* \< 0.001). In multivariate analysis, initial stroke severity (OR 8.94, CI 5.01-15.94, *P* \< 0.001) and degree of stenosis (OR 2.00, CI 0.99-4.05, *P* = 0.053) were independent predictors of poor functional outcome at 90 days \[[Table 2](#T2){ref-type="table"}\]. No predictor of recurrent stroke/TIA was identified \[[Table 3](#T3){ref-type="table"}\].

###### 

Multivariable logistic regression models of poor functional outcome at 3 months

  Variable                    Odds ratio (OR)   95% confidence interval for OR   *P*      
  --------------------------- ----------------- -------------------------------- -------- ---------
  Age                         1.021             0.997                            1.046    0.093
  Sex                         0.602             0.336                            1.080    0.089
  HTN                         0.565             0.268                            1.191    0.133
  DM                          1.625             0.903                            2.924    0.105
  CAD                         1.178             0.569                            2.442    0.659
  Smoking                     1.373             0.679                            2.778    0.378
  NIHSS \>5                   8.936             5.012                            15.935   \<0.001
  DAPT on discharge           1.086             0.573                            2.058    0.800
  Statin on discharge         0.354             0.102                            1.232    0.103
  Degree of stenosis (≥70%)   2.003             0.990                            4.051    0.053

###### 

Multivariable logistic regression models of recurrent stroke/TIA at 3 months

  Variable                    *P*     Odds ratio (OR)   95% confidence interval for OR   
  --------------------------- ------- ----------------- -------------------------------- -------
  Age                         0.608   0.993             0.969                            1.019
  Sex                         0.118   0.620             0.340                            1.129
  HTN                         0.071   2.389             0.929                            6.143
  DM                          0.098   0.609             0.339                            1.096
  CAD                         0.650   1.184             0.570                            2.459
  Smoking                     0.850   0.929             0.436                            1.980
  DAPT on discharge           0.481   1.273             0.650                            2.493
  Statin on discharge         0.837   0.862             0.210                            3.541
  Degree of stenosis (≥70%)   0.155   1.703             0.817                            3.552
  ICAD location (anterior)    0.826   1.072             0.578                            1.986

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Comprising 25% of the world\'s population, South Asians are a rapidly growing ethnic group with unique genetic, biologic, and environmental risk factors.\[[@ref15]\] Stroke mortality among Indians is higher compared to Whites in developed countries.\[[@ref16][@ref17]\] The greater burden and severity of vascular risk factors among South Asians likely accounts for the greater incidence and severity of vascular events. Furthermore, previous studies have shown that South Asians experience stroke at younger ages.\[[@ref3][@ref18]\] The Indo-US Stroke project\[[@ref19]\] found Indian patients to be younger and have differing risk factor profile. Although genetics are believed to contribute to the elevated risk of stroke among South Asians, there are also regional variations that are likely influenced by geographic characteristics, diet, availability of medical care and socioeconomic status. Although Asians experience more severe strokes, they are less likely to have recurrent strokes. In a large cohort from China,\[[@ref9]\] recurrent stroke risk was 6% at 1 year follow-up, which was considerably lower than the Western population.

Several studies have shown a strong association between diabetes and stroke in South Asians. The South Asians, especially males, are at a disproportionately higher risk of developing diabetes and at a younger age due to biological and lifestyle factors compared to other ethnic groups.\[[@ref20]\] This increased prevalence of diabetes has been associated with increase in incident stroke, stroke recurrence, and stroke mortality.\[[@ref21][@ref22][@ref23][@ref24]\] South Asians have been observed to have a significantly higher prevalence of prediabetes and diabetes than other US ethnic groups (Chinese Americans, Whites, African Americans, Latinos).\[[@ref20]\]

Exposure to atherosclerotic risk factors such as diabetes and smoking may explain some of our findings. Prior studies have documented that diabetes is strongly associated with ICAD in a mixed ethnic cohort in the US.\[[@ref25]\] Greater prevalence of diabetes among South Asians may be a major determinant of ICAD in this population and may also contribute to our finding of earlier onset of disease and greater stroke severity in Indian population.\[[@ref26]\] Secondly, smokers develop stroke at a younger age as compared to non-smokers.\[[@ref27]\] In a cohort of patients with ICAD from Korea,\[[@ref28]\] smokers were more likely to have stroke at a younger age, specifically \< 70 years of age. Higher prevalence of smoking in Indian males may further contribute to younger age of Indian patients. Finally, patients on antiplatelets prior to stroke have been reported to have reduced stroke severity, especially for large artery atherosclerotic etiology.\[[@ref26]\] The US patients were more likely to be on antiplatelets prior to current stroke, which may also have contributed to reduced stroke severity in them.

Despite greater severity and younger age at time of index stroke, Indian patients had significantly fewer recurrent strokes as compared to the cohort from US. Dual antiplatelet therapy was more commonly prescribed in the Indian cohort for 3 months after stroke, which may reduce recurrent stroke risk as found in the medical management arm of the SAMMPRIS trial.\[[@ref6]\] However, in study by Sangha *et al*.,\[[@ref29]\] ICAD patients on dual antiplatelets had same risk of recurrence as patients not on dual antiplatelets. Although Indian patients had fewer recurrent strokes, they had more TIAs at 3 months. This may be explained by the reduced severity of recurrent strokes, as they were more commonly on dual antiplatelets.\[[@ref26]\] Control of risk factors, which was a part of aggressive medical management in SAMMPRIS trial, is an important factor which reduces the stroke recurrence in ICAD, but meticulous information of risk factor control was not available from our patients. Detailed analysis of imaging data including involvement of other intracranial vessels and presence of collaterals, may also help in assessing risk of recurrence.

Initial stroke severity has been reported to be a significant predictor of 3-month functional outcome.\[[@ref30]\] Indian patients had more severe strokes at onset and more functional disability at 3 months. Even after adjusting for age and risk factors, initial stroke severity was the most significant predictor for poor functional outcome in our study.

Severity of stenosis has been reported as risk factor for recurrent events.\[[@ref13]\] However, its contribution to functional outcome has not been reported previously. We found that severity of stenosis was a significant predictor for poor functional outcome.

Strengths of the study {#sec2-7}
----------------------

Our study relied on stroke neurologist and neuroradiologist adjudicated diagnosis of intracranial atherosclerosis based on high-quality imaging - CT angiography or MR angiography in all the cases. All patients were extensively evaluated to rule out alternative etiologies for stroke. Although it was a retrospective study, parameters like recurrent events, functional status were evaluated and regularly documented by experienced neurologists at scheduled follow-ups, giving comprehensive and reliable data.

Limitations {#sec2-8}
-----------

Risk factor control, an important factor which predicts stroke recurrence, was not available from our study. Recurrent TIA was a clinical diagnosis and imaging data was not available for all patients. The Indian patients were a homogenous sample but patients from the US consisted of multiethnic group and hence may not be homogenous. Since many of the milder strokes may not have visited the hospitals in India, the baseline increased stroke severity of Indian patients may be a sampling bias in the study.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

We observed that symptomatic ICAD in India is associated with greater stroke severity and younger age at index presentation. Despite this, the treatment with dual antiplatelets may have reduced the stroke recurrence in Indian patients.
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